Advice
following an abbreviated submission
solifenacin succinate plus tamsulosin hydrochloride 6mg / 0.4mg modified release tablet (Vesomni®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.
In patients for whom concomitant use of solifenacin succinate and tamsulosin hydrochloride is appropriate, Vesomni® allows administration of a single tablet at a lower cost compared to the individual components administered separately.
Download detailed advice76KB (PDF)
Medicine details
- Medicine name:
- solifenacin and tamsulosin (Vesomni)
- SMC ID:
- 945/14
- Indication:
- For the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 March 2014